Sweden has reached the UNAIDS and WHO targets for the HIV epidemic, according to a study in Eurosurveillance by researchers ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...

The national HIV prevalence was 16. 3% among adults aged 15 years and older, translating to an estimated 7. 4 million adults ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

The availability of such kidney transplants outside of the research setting could substantially improve organ availability ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

Sweden has reached the UNAIDS and WHO targets for the HIV epidemic, according to a study in Eurosurveillance by researchers ...

The researchers found that 80% of those who got a short course of chemotherapy first lived at least five more years, and 72% ...

While the numbers of people with HIV remains high, treatment and preventative medications ... Based on data from its trials, Gilead said it is beginning a series of regulatory filings by the ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...